^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Ocular Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Title:

    trametinib (Mekinist®) is accepted for restricted use within NHSScotland.

    Excerpt:
    trametinib (Mekinist) is accepted for restricted use within NHSScotland....in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Ocul Oncol Pathol
    Title:

    Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma

    Published date:
    06/26/2019
    Excerpt:
    The authors report the case of a 52-year-old Caucasian male with unresectable, recurrent conjunctival melanoma with V600 BRAF mutation who was treated with systemic BRAF/MEK inhibition….There was complete regression of local disease within the first 9 months. The patient remains without local recurrence or systemic metastasis at 1 year.
    DOI:
    https://doi.org/10.1159/000497473